Prapiadou S, Živković L, Thorand B, et al. Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis. Circulation. 2023. doi:10.1161/CIRCULATIONAHA.123.064974.
Prapiadou S, Živković L, Thorand B, et al. Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis. medRxiv : the preprint server for health sciences. 2023. doi:10.1101/2023.03.24.23287543.
Prapiadou S, Živković L, Thorand B, et al. Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis. medRxiv : the preprint server for health sciences. 2023. doi:10.1101/2023.03.24.23287543.
Kitajima S, Yoshida A, Kohno S, et al. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene. 2017;36(36):5145-5157. doi:10.1038/onc.2017.124.
Freitas CG, Lima SMF, Freire MS, et al. An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.02518-16.
Verma MS, Fink MJ, Salmon GL, et al. A Common Mechanism Links Activities of Butyrate in the Colon. ACS Chem Biol. 2018;13(5):1291-1298. doi:10.1021/acschembio.8b00073.
Schnabel RB, Yin X, Larson MG, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol. 2013;33(7):1728-33. doi:10.1161/ATVBAHA.112.301174.
Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452-65. doi:10.1158/2159-8290.CD-13-0646.
Fall T, Hägg S, Ploner A, et al. Age- and sex-specific causal effects of adiposity on cardiovascular risk factors. Diabetes. 2015;64(5):1841-52. doi:10.2337/db14-0988.